None
Quote | PerkinElmer Inc. (NYSE:PKI)
Last: | $115.24 |
---|---|
Change Percent: | 0.28% |
Open: | $115.98 |
Close: | $115.24 |
High: | $117.21 |
Low: | $114.67 |
Volume: | 1,633,026 |
Last Trade Date Time: | 05/15/2023 03:00:00 am |
News | PerkinElmer Inc. (NYSE:PKI)
2023-05-11 14:02:09 ET Revvity Inc. (PKI) Q1 2023 Earnings Conference Call May 11, 2023, 08:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President and CEO Max Krakowiak - SVP and CFO Miriame Victor - Chief Commercial Officer ...
2023-05-11 06:03:29 ET PerkinElmer press release ( NYSE: PKI ): Q1 Non-GAAP EPS of $1.01 misses by $0.01 . Revenue of $674.86M (-29.9% Y/Y) misses by $3.75M . The company’s stock ticker will change from PKI to RVTY with the beginning of trading on May 16...
Message Board Posts | PerkinElmer Inc. (NYSE:PKI)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $PKI News Article - PerkinElmer Announces Financial Results for the Second Quarter of 2 | whytestocks | investorshangout | 08/01/2022 3:01:01 PM |
whytestocks: $PKI News Article - PerkinElmer Accelerates Transformation into High Growth, High Margi | whytestocks | investorshangout | 08/01/2022 2:55:59 PM |
whytestocks: $PKI News Article - U.S. Centers for Disease Control Guidance Includes EUROIMMUN Assay | whytestocks | investorshangout | 02/03/2022 1:30:49 PM |
whytestocks: $PKI News Article - Shares of PerkinElmer Inc. (PKI) Have Risen Above Previous 52-Week | whytestocks | investorshangout | 07/26/2021 7:00:50 PM |
whytestocks: $PKI News Article - PerkinElmer Announces Financial Results for the Second Quarter of 2 | whytestocks | investorshangout | 07/26/2021 6:45:50 PM |
News, Short Squeeze, Breakout and More Instantly...
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVI...
Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin tradi...
Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world’s greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on ...